Apixaban for Extended Treatment of Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo in patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy and for whom there was clinical equipoise regarding the continuation or cessation of anticoagulation therapy. The study drugs were administered for 12 months. RESULTS: A total of 2486 patients underwent randomization, of whom 2482 were included in the intention-to-treat analyses. Symptomatic recurrent venous thromboembolism or death from venous thromboembolism occurred in 73 of the 829 patients (8.8%) who were receiving placebo, as compared with 14 of the 840 patients (1.7%) who were receiving 2.5 mg of apixaban (a difference of 7.2 percentage points; 95% confidence interval [CI], 5.0 to 9.3) and 14 of the 813 patients (1.7%) who were receiving 5 mg of apixaban (a difference of 7.0 percentage points; 95% CI, 4.9 to 9.1) (P<0.001 for both comparisons). The rates of major bleeding were 0.5% in the placebo group, 0.2% in the 2.5-mg apixaban group, and 0.1% in the 5-mg apixaban group. The rates of clinically relevant nonmajor bleeding were 2.3% in the placebo group, 3.0% in the 2.5-mg apixaban group, and 4.2% in the 5-mg apixaban group. The rate of death from any cause was 1.7% in the placebo group, as compared with 0.8% in the 2.5-mg apixaban group and 0.5% in the 5-mg apixaban group. CONCLUSIONS: Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding. (Funded by Bristol-Myers Squibb and Pfizer; AMPLIFY-EXT ClinicalTrials.gov number, NCT00633893.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For the baseline risk of major bleeding, we used data from 2 randomized trials on people with VTE, showing that the risk of major bleeding with placebo during 18 or 24 months of follow-up was as low as 0.5% 306 and as high as 1.5% in 18 months. 259”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“We identified 2 RCTs 306,314 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“Two of these agents, rivaroxaban and apixaban, have been studied at a reduced dose: from 20 mg daily to 10 mg daily for rivaroxaban and 5 mg to 2.5 mg twice daily for apixaban. 306,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
Citations
Cites
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F., Brady, A. J. B., Ferreira, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn310 · Cited by 2,826
Self-citationApixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Pulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Self-citationAspirin for Preventing the Recurrence of Venous Thromboembolism
Becattini, C., Agnelli, G., Schenone, A., Eichinger, S., Bucherini, E., Silingardi, M., Bianchi, M., Moia, M., Ageno, W., Vandelli, M. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114238 · Cited by 620
Self-citation
Research works printed but not linked: 1
- Schulman S, 2011, J Thromb Haemost, 9, 22
Cited by
Items 601–700 of 1,000
Five-year follow-up of pulmonary embolism under anticoaugulation
Marconi, L., Carrozzi, L., Aquilini, F., Celi, A., Pistelli, F., & Palla, A. (2016) · Medicine · doi:10.1097/md.0000000000004364 · Cited by 13
Voukalis, C., Lip, G. Y. H., & Shantsila, E. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1232393 · Cited by 10
“Dabigatran RE-MEDY [89] 2886 150 mg BID /warfarin 6–36 Non-inferior No significant increase in major bleeding Dabigatran RE-SONATE [89] 1353 150 mg BID /placebo 12 Superior No significant increase in major bleeding Rivaroxaban EINSTEIN-EXT [11] 1197 20 mg OD /placebo 6 or 12 Superior No significant increase in major b…”
BackgroundFeuring, M., Schulman, S., Eriksson, H., Kakkar, A. K., Schellong, S., Hantel, S., Schueler, E., Kreuzer, J., & Goldhaber, S. Z. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1479-z · Cited by 9
Utility of the DASH score after unprovoked venous thromboembolism; a single centre study
MacDonald, S. G., Chengal, R., Hanxhiu, A., Symington, E. M., Sheares, K. K. K., Besser, M. W., & Thomas, W. (2018) · British Journal of Haematology · doi:10.1111/bjh.15597 · Cited by 9
“Our findings suggest rates above this; however, this threshold is debatable with low dose direct oral anti-coagulants which have a favourable bleeding profile (Agnelli et al, 2013 & Weitz et al, 2017).”
BackgroundDiagnosis and management of congenital thrombophilia in the era of direct oral anticoagulants
Alameddine, R., Nassabein, R. M., Gal, G. L., Siè, P., Mullier, F., & Blais, N. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.11.008 · Cited by 13
Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism
Riva, N., & Ageno, W. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.05.008 · Cited by 9
Howe, Z., Naville-Cook, C., & Cole, D. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1770-7 · Cited by 8
Dix, C. H. K., Doyle, A. J., Breen, K. A., & Hunt, B. J. (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2379-7288 · Cited by 8
Hoberstorfer, T., Nopp, S., Steiner, D., Blasco, L., Jou, I., López-Núñez, J. J., Fidalgo, Á., López-Miguel, P., Monréal, M., Ay, C., et al. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.08.007 · Cited by 8
Schmerge, M., Earl, S. R., & Kline, C. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000043 · Cited by 8
Invasive and Pharmacological Treatment of Deep Vein Thrombosis: A Scoping Review
Sagris, Μ., Tzoumas, A., Kokkinidis, D. G., Korosoglou, G., Lichtenberg, M. K. W., & Tzavellas, G. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220418084339 · Cited by 10
Fan, G., Wang, D., Zhang, M., Luo, X., Zhai, Z., & Wu, S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.979911 · Cited by 9
Ma, S., Fan, G., Xu, F., Zhang, X., Chen, Y., Tao, Y., Li, Y., Lyu, Y., Yang, P. B., Wang, D., et al. (2024) · Thrombosis Journal · doi:10.1186/s12959-023-00576-2 · Cited by 9
“Moreover, AMPLIFY-EXT also compared the efficacy and safety of low-dose NOACs vs placebo [30].”
BackgroundDirect oral anticoagulants for treatment of venous thrombosis: illustrated review of appropriate use
Khairani, C. D., Bejjani, A., Assi, A. A., Porio, N. D., Talasaz, A. H., Piazza, G., Cushman, M., & Bikdeli, B. (2024) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2024.102424 · Cited by 10
The target-specific oral anticoagulants: practical considerations
Garcia, D. A. (2014) · Hematology · doi:10.1182/asheducation-2014.1.510 · Cited by 8
Liew, A., & Douketis, J. D. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.770838 · Cited by 8
“2 Apixaban Apixaban is another oral factor Xa inhibitor which was evaluated in the AMPLIFY-EXT trial [12].”
MethodDevelopment of New Deep Venous Thrombosis While on Apixaban
Sharma, M., Ramanathan, S., & Khalighi, K. (2017) · Case Reports in Cardiology · doi:10.1155/2017/2842935 · Cited by 9
Saleh, A. S. A., Berrigan, P., Anderson, D. R., & Shivakumar, S. (2017) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v70i3.1658 · Cited by 9
Direct oral anticoagulants and travel-related venous thromboembolism
Chamnanchanunt, S., & Rojnuckarin, P. (2018) · Open Medicine · doi:10.1515/med-2018-0085 · Cited by 8
“The recommendation still suggests LMWH therapy for VTE patients with active malignancy because those patients attributed to small subgroups in DOACs studies [31-38,4042,45,46].”
BackgroundInfluentialKeller, K., Göbel, S., ten Cate, V., Panova‐Noeva, M., Eggebrecht, L., Nagler, M., Coldewey, M., Foebel, M., Bickel, C., Lauterbach, M., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103281 · Cited by 9
“In RMC and likewise in all registration trials for DOACs in VTE patients, the time spent below the therapeutic range was substantial [1,7,27,33], which entails an elevated risk of thromboembolic events and is therefore undesirable in VTE patients [34,35].”
BackgroundKaneda, K., Yamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.11.022 · Cited by 11
Outpatient treatment of pulmonary embolism
Bellou, E., Keramida, E., Karampinis, I., Dimakakos, E. P., Misthos, P. A., Demertzis, P., & Hardavella, G. F. (2020) · Breathe · doi:10.1183/20734735.0069-2020 · Cited by 8
“NOACs are the new gold standard for anticoagulation therapy due to their lower bleeding rates compared with VKAs [6, 30, 31].”
BackgroundHow, J., Story, C. M., & Connors, J. M. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1880844 · Cited by 8
“thrombosis with prophylactic dosing after 6–12 months of DOAC treatment at therapeutic dosing levels [76,77].”
BackgroundWhen and how to use direct oral anticoagulants in patients with advanced chronic liver disease?
Maria, C. D., Galante, A., Fasoli, A., & Gottardi, A. D. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.07.006 · Cited by 8
Tanislav, C., Rosenbauer, J., Zingel, R., & Kostev, K. (2022) · Public Health · doi:10.1016/j.puhe.2022.03.004 · Cited by 10
Rayani, R. H., Soni, J. Y., Parmar, D. R., Kusurkar, R. V., Eissa, I. H., Metwaly, A. M., Khalil, A., Zunjar, V., Battula, S., & Niazi, S. (2022) · Results in Chemistry · doi:10.1016/j.rechem.2022.100355 · Cited by 8
Ferns, S. J., & Naccarelli, G. V. (2015) · Medical Clinics of North America · doi:10.1016/j.mcna.2015.02.006 · Cited by 8
Beyer‐Westendorf, J., Gehrisch, S., Stange, T., Tittl, L., Siegert, G., & Weiss, N. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.06.003 · Cited by 8
“8% [20].”
Apixaban and risk of myocardial infarction: meta-analysis of randomized controlled trials
Tornyos, A., Vorobcsuk, A., Kupó, P., Aradi, D., Kehl, D., & Komócsi, A. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1096-z · Cited by 10
“Two trials were preformed in patients after deep vein thrombosis (DVT) and/or pulmonary embolism (PE) [11, 12].”
Latest developments in anticoagulant drug discovery
Broussalis, E., Anna, W., Trinka, E., Mutzenbach, J. S., & Killer‐Oberpfalzer, M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.02.011 · Cited by 10
Anticoagulation in Pulmonary Embolism: Update in the Age of Direct Oral Anticoagulants
Rosovsky, R. P. G., & Merli, G. J. (2017) · Techniques in vascular and interventional radiology · doi:10.1053/j.tvir.2017.07.003 · Cited by 8
Massive Spontaneous Hemothorax as a Complication of Apixaban Treatment
Abu-Hishmeh, M., Srivastava, P., Lougheide, Q., Srinivasan, M., & Murthy, S. (2018) · Case Reports in Pulmonology · doi:10.1155/2018/8735036 · Cited by 9
“Apixaban is a DOAC used to prevent stroke or thromboembolic events in patients with nonvalvular atrial fibrillation and to prevent recurrent venous thromboembolic disease [13, 14].”
BackgroundDjulbegovic, M., Lee, A. I., & Chen, K. M. (2019) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13194 · Cited by 9
Κάρτας, Α., Doundoulakis, I., Ntiloudi, D., Koutsakis, A., Kosmidis, D., Rampidis, G. P., Apostolopoulou, S. C., Frogoudaki, A., Tzifa, A., Avramidis, D., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-038012 · Cited by 9
DeRemer, C. E., Dietrich, E. A., Kang, H., Huang, P., Lo‐Ciganic, W., & Park, H. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13462 · Cited by 9
Mauger, C., Gouin‐Thibault, I., Guéret, P., Nédelec-Gac, F., Baillerie, A., Lefeuvre, C. P., Boutruche, B., Bayard, S., Jaquinandi, V., Jégo, P., et al. (2020) · JMV-Journal de Médecine Vasculaire · doi:10.1016/j.jdmv.2020.04.011 · Cited by 9
Kanthi, Y. M., & Piazza, G. (2018) · Vascular Medicine · doi:10.1177/1358863x18770529 · Cited by 8
“23(4) 384 –387 © The Author(s) 2018 Reprints and permissions: sagepub.”
Barrios, V., & Escobar, C. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1053871 · Cited by 8
Kommentar zur 2014-ESC-Leitlinie zum Management der akuten Lungenembolie
Konstantinides, S., Bauersachs, J. K., Mayer, E., & Hambrecht, R. (2015) · Der Kardiologe · doi:10.1007/s12181-015-0008-6 · Cited by 7
Riva, N., & Ageno, W. (2015) · PubMed · doi:10.2450/2015.0057-15 · Cited by 9
Direct Oral Anticoagulants for Pulmonary Embolism
Pizzi, R., Cimini, L. A., Ageno, W., & Becattini, C. (2024) · Hämostaseologie · doi:10.1055/a-2105-8736 · Cited by 9
Palareti, G., Legnani, C., Tosetto, A., Poli, D., Testa, S., Ageno, W., Pengo, V., Cosmi, B., & Prandoni, P. (2024) · Thrombosis Research · doi:10.1016/j.thromres.2024.04.018 · Cited by 7
Costanzo, L., Paola, F. D., Pedi, A., Failla, G., & Mangiafico, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13082394 · Cited by 8
Anticoagulants: From chance discovery to structure-based design
Chan, N., Carlin, S., & Hirsh, J. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100037 · Cited by 7
The role of novel anticoagulants in the management of venous thromboembolism
Skeik, N., Murphy, C. J., & Porten, B. R. (2014) · Vascular Medicine · doi:10.1177/1358863x14534309 · Cited by 7
Venous thromboembolism management: where do novel anticoagulants fit?
Spyropoulos, A. C., & Turpie, A. G. G. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.803462 · Cited by 7
Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
Gibson, C. M., & Finks, S. W. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.02.048 · Cited by 7
Ueshima, S., Hira, D., Tomitsuka, C., Nomura, M., Kimura, Y., Yamane, T., Tabuchi, Y., Ozawa, T., Itoh, H., Horie, M., et al. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0353-7 · Cited by 7
Methodological Issues and Controversies in COVID-19 Coagulopathy: A Tale of Two Storms
Berkman, S. A., & Tapson, V. F. (2020) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029620945398 · Cited by 7
“The risk of major bleeding on low-dose DOAC prophylaxis would appear to be low when considering the available data from(30) MARINER,(21) as well as the EINSTEIN CHOICE(34) and AMPLIFY-EXTEND trials.(35)”
Direct oral anticoagulant dose selection: Challenging cases
Carlin, S., & Eikelboom, J. W. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15536 · Cited by 7
Kang, H., Lo‐Ciganic, W., DeRemer, C. E., Dietrich, E. A., Huang, P., & Park, H. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2611 · Cited by 7
“Similarly, another clinical trial, Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with FirstLine TherapyExtended Treatment (AMPLIFYEXT), demonstrated that extended treatment with apixaban decreased recurrent VTE rates without increasing the rate of major bleeding events compared w…”
ResultBleeding complications in patients on new oral anticoagulants for venous thromboembolism in Kenya
Obayo, A., Ngunga, M., Shah, J., Sokwala, A. P., & Barasa, A. L. (2022) · Cardiovascular journal of South Africa/Cardiovascular journal of Southern Africa · doi:10.5830/cvja-2021-060 · Cited by 7
Liu, Z., Tan, J., Deng, Y.-R., Hua, L., & Guo, T. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9120414 · Cited by 7
A systematic update on the state of novel anticoagulants and a primer on reversal and bridging
Knepper, J. P., Horne, D. C., Andrea, T., & Wakefield, T. W. (2013) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2013.04.006 · Cited by 9
Update on Pharmacologic Therapy for Pulmonary Embolism
Harikrishnan, P., Palaniswamy, C., & Aronow, W. S. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413506612 · Cited by 9
“5 mg and 5 mg, twice daily) were compared with placebo in 2486 patients with VTE who completed 6 to 12 months of anticoagulation and for whom treating physicians were uncertain about continuing therapy.(50) The study drugs were given for 1 year.”
MethodSafety of apixaban for venous thromboembolism prophylaxis: the evidence to date
Trkulja, V. (2016) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s74410 · Cited by 9
“5 mg BID or 5 mg BID was comparable to placebo regarding all adverse events (type, incidence, severity), apart from a trend toward a greater incidence of bleeding.(50) Therefore, as with other DOACs, the risk of bleeding is the only specific safety concern associated with the use of apixaban in the VTE setting.”
Non-vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism
Bauersachs, R. M. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.05.022 · Cited by 7
“Phase III extended treatment studies of non-vitamin K antagonist oral anticoagulants for the long-term prevention of recurrent symptomatic venous thromboembolism EINSTEIN EXT [23] AMPLIFY-EXT [28] RE-SONATE [26] RE-MEDY [26]”
BackgroundInfluentialAn update on the pharmaceutical management of thrombosis
Cosmi, B. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1241233 · Cited by 8
“dose or 5 mg twice daily compared to patients taking placebo to determine the effects of apixaban on recurrent VTE [66].”
BackgroundThe Treatment of Venous Thromboembolism in Patients with Cancer
Prandoni, P. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_111 · Cited by 7
Enea, I., Roncon, L., Gulizia, M. M., Azzarito, M., Becattini, C., Bongarzoni, A., Casazza, F., Cuccia, C., D’Agostino, C., Rugolotto, M., et al. (2017) · European Heart Journal Supplements · doi:10.1093/eurheartj/sux026 · Cited by 7
“placebo in the AMPLIFY-Extension study.(8) Both 2.”
Farinola, N., Caughey, G. E., Bell, J. S., Johns, S., Hauta‐aho, M., & Shakib, S. (2017) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098617747835 · Cited by 7
van der Pol, L. M., Mairuhu, A. T. A., Leroyer, C., Couturaud, F., Huisman, M., Klok, F. A., & Tromeur, C. (2018) · Seminars in Interventional Radiology · doi:10.1055/s-0038-1642622 · Cited by 10
Extended anticoagulation for unprovoked venous thromboembolism
Castellucci, L. A., de Wit, K., Garcia, D. A., Ortel, T. L., & Gal, G. L. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12121 · Cited by 7
Riva, L., Ageno, W., Pasquale, G. D., Agnelli, G., & Rubboli, A. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.07.133 · Cited by 7
Self-citationReal-world assessment of off-label direct oral anticoagulant dosing for venous thromboembolism
Saunders, J. A., Gustafson, W. L., Vazquez, S. R., Jones, A. E., & Witt, D. M. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01904-y · Cited by 7
Is there a role for low-dose DOACs as prophylaxis?
Cohen, A. T., & Hunt, B. J. (2019) · Hematology · doi:10.1182/hematology.2019000026 · Cited by 7
Self-citationWang, J., Lim, H. Y., Brook, R., Lai, J., Nandurkar, H. H., & Ho, P. W. (2022) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-022-02686-6 · Cited by 8
“The high proportion of long-term anticoagulation may reflect current clinical practice following evidence supporting the use of long-term low-dose direct oral anticoagulants [27, 28].”
BackgroundOral Anticoagulation in the Elderly: New Oral Anticoagulants–Innovative Solution for an Old Problem?
Barbosa, M., & Falcão, L. M. (2016) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000452 · Cited by 9
Renal function and venous thromboembolic diseases
Janus, N., Mahé, I., Launay‐Vacher, V., Laroche, J.-P., & Deray, G. (2016) · Journal des Maladies Vasculaires · doi:10.1016/j.jmv.2016.09.001 · Cited by 7
Hong, K. (2019) · Journal of Stroke · doi:10.5853/jos.2019.01970 · Cited by 7
“7%).(68) In Phase 3, Randomized, Parallel-Group, Multi-Center, MultiNational Study for the Evaluation of Efficacy and Safety of Heparin/Edoxaban Versus Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis and or Pulmonary Embolism (Hokusai-VTE; n=8,292), edoxaban 60 mg (30 mg for CrCL 30 to 50 mL/min or…”
BackgroundUsing non-vitamin K oral anticoagulants in specific patient populations: a study of Korean cases
-, I. C. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s204377 · Cited by 7
“5 mg twice daily) than with placebo, without a significant increase in bleeding rates.(35) In the EINSTEINCHOICE study, extended anticoagulation with rivaroxaban at either a full-dose (20 mg once daily) for treatment and prophylaxis of VTE or a reduced-dose (10mg once daily) significantly lowered the risk of recurrent…”
BackgroundMethodInfluentialSecondary Prevention of Venous Thromboembolism: One Regimen May Not Fit All
Blondon, M., & Bounameaux, H. (2015) · Circulation · doi:10.1161/circulationaha.115.019310 · Cited by 10
Piazza, G. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac731 · Cited by 8
Eichinger, S., Lin, M., Shi, M., GROSSO, M. A., & Kyrle, P. A. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.07.028 · Cited by 6
Pathway for the Diagnosis and Management of Pulmonary Embolism
Herzog, E., Elbaz‐Greener, G., Planer, D., Koren, T., Amir, O., Shapiro, J. M., & Kalish, Y. (2021) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000252 · Cited by 6
“as a first choice based on their excellent safety profile and their excellent extended treatment data (11-13).”
BackgroundKang, H., Jones, B. L., Lo‐Ciganic, W., DeRemer, C. E., Dietrich, E. A., Pei-lin, H., & Park, H. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.100131 · Cited by 8
Direct Oral Anticoagulants for Inferior Vena Cava Agenesis
Iarossi, M., & Hermans, C. R. J. R. (2023) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296231200224 · Cited by 6
Wang, J., Liu, Y., Yan, Y., Liu, L., Zhang, C., Pan, M.-M., Lin, H., & Gu, Z. (2023) · Journal of Interventional Cardiology · doi:10.1155/2023/4717271 · Cited by 6
Guidelines on deep vein thrombosis of the Brazilian Society of Angiology and Vascular Surgery
Sobreira, M. L., Marques, M. A., Paschôa, A. F., Ribeiro, A. J. A., Casella, I. B., Burihan, M. C., Matielo, M. F., Soares, R. D. A., de Araújo, W. J. B., Joviliano, E. É., et al. (2024) · Jornal Vascular Brasileiro · doi:10.1590/1677-5449.202301072 · Cited by 8
“91,94,95 There is no need for concomitant use of parenteral anticoagulants.”
BackgroundAlam, U., Ali, M. A., Ansab, M., Rath, S., Khattak, F., Bacha, Z., Siddiqui, H. T., Sajjad, F., Afridi, A., Afridi, Z., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04388-1 · Cited by 6
“Eighty-two full-text articles were assessed for eligibility; five studies were included in the qualitative and quantitative synthesis Agnelli et al. (2013), Couturaud (2025), Mahè (2025), McBane (2024), Weitz (2017).”
InfluentialPulmonary embolism hotline 2012: Recent and expected trials
Lankeit, M., & Konstantinides, S. (2013) · Hämostaseologie · doi:10.5482/hamo-12-12-0024 · Cited by 6
Scoring Systems for Estimating the Risk of Recurrent Venous Thromboembolism
Nichele, I., & Tosetto, A. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1602662 · Cited by 7
Lungenarterienembolie: Status 2018
Wilkens, H., & Held, M. (2018) · Deutsches Ärzteblatt · doi:10.3238/perspneumo.2018.06.15.002 · Cited by 8
Folkerts, K., Broughton, J., Sheikh, U., & Mckaig, S. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1658589 · Cited by 8
Direct Oral Anticoagulants in Antithrombin Deficiency: Initial Experience in a Single Center
Bhoelan, S., Mulder, R., Lukens, M. V., & Meijer, K. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1715647 · Cited by 6
Management of acute venous thromboembolism in patients taking antiplatelet therapy
Giraud, M., Catella, J., Cognet, L., Helfer, H., Accassat, S., Chapelle, C., Mismetti, P., Laporte, S., Mahé, I., & Bertoletti, L. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.11.001 · Cited by 6
Fukamachi, D., Okumura, Y., Fukuda, I., Nakamura, M., Yamada, N., Takayama, M., Maeda, H., Yamashita, T., Ikeda, T., Mo, M., et al. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2070379 · Cited by 6
An Update in Anticoagulant Therapy for Patients with Cancer-Associated Venous Thromboembolism
Martins, M. D. A., Silva, T. F., & Fernandes, C. J. C. D. S. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01384-7 · Cited by 7
The place of new oral anticoagulants in travel medicine
Ringwald, J., Grauer, M., Eckstein, R., & Jelínek, T. (2013) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2013.11.005 · Cited by 8
Aspirin in secondary prevention of recurrent venous thromboembolism
Boonyawat, K., & Crowther, M. A. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1196-4 · Cited by 6
Frost, C. E., Nepal, S., Byon, W., Moore, K. T., Reeves, R. A., Boyd, R. A., & LaCreta, F. P. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.447 · Cited by 6
Sista, A. K. (2014) · Techniques in vascular and interventional radiology · doi:10.1053/j.tvir.2014.02.011 · Cited by 6
“Dabigatran and apixaban have also shown promise in extension therapy, based on the results of RE-MEDY, RE-SONATE (dabigatran),(25) and AMPLIFY-Extension (apixaban).(26)”
ResultThe Current and Future Role of the Novel Oral Anticoagulants—Indications Beyond Atrial Fibrillation
Lee, A., & Rajaratnam, R. (2013) · Heart Lung and Circulation · doi:10.1016/j.hlc.2013.09.007 · Cited by 6
“The AMPLIFY-EXT study [26] was a randomised, doubleblind, superiority trial testing extended therapy with two doses of apixaban compared to placebo in 2486 patients whom had already completed six to 12 months of standard anticoagulation therapy with either warfarin or apixaban as part of the ongoing AMPLIFY trial.”
MethodThe pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism
Escolar, G., Díaz‐Ricart, M., Arellano‐Rodrigo, E., & Galan, A. M. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.882897 · Cited by 7
Update on Anticoagulation: What the Interventional Radiologist Needs to Know
Kamath, S. D., & McMahon, B. J. (2016) · Seminars in Interventional Radiology · doi:10.1055/s-0036-1582124 · Cited by 6
Freed, J. A., & Bauer, K. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00014-5 · Cited by 6
Modern position of anticoagulants in acute pulmonary embolism: achievements, limitations, prospects
Terekhovskaya, Y. V., Okorokov, V. G., & Николаевна, Н. Н. (2019) · I P Pavlov Russian Medical Biological Herald · doi:10.23888/pavlovj201927193-106 · Cited by 7
Siniscalchi, C. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.04.026 · Cited by 6
Banham-Hall, E., Allison, A., Santarsieri, A., Gohel, M., Crowley, M. P., Sheares, K. K. K., & Thomas, W. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02193-6 · Cited by 6
Villa, V. B., Romero, J. G., Rojas‐Zaldivar, E., Cervantes, M., Villa‐Márquez, M. D. R., Baz, P., & Cesarman-Maus, G. N. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12492 · Cited by 6
Metadata
- Authors
- Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I.
- Affiliations
- University of Perugia (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- King's College Hospital (GB)
- McMaster University (CA)
- Flinders University (AU)
- University of Oklahoma Health Sciences Center (US)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-02-21
- Volume
- 368
- Issue
- 8
- Pages
- 699-708
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139785591
- Cited by
- 1,366
- References
- 19
- Citations by year
- 2026: 70 · 2025: 80 · 2024: 64 · 2023: 68 · 2022: 90 · 2021: 98 · 2020: 101 · 2019: 114 · 2018: 103 · 2017: 89 · 2016: 109 · 2015: 133 · 2014: 141 · 2013: 102
- FWCI
- 81.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Bayer HealthCare
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, venous thromboembolism, long-term anticoagulation, factor Xa inhibitors, recurrent venous thromboembolism, thromboprophylaxis, major bleeding, mortality, dose comparison, oral anticoagulants, clinical equipoise, post-thrombotic syndrome, pulmonary embolism, deep vein thrombosis
- MeSH terms
- Adult, Aged, Creatinine, Double-Blind Method, Female, Fibrinolytic Agents, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Recurrence, Treatment Outcome, Kaplan-Meier Estimate, Venous Thromboembolism, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.